van Netten J P, Armstrong J B, Carlyle S S, Goodchild N L, Thornton I G, Brigden M L, Coy P, Fletcher C
Department of Pathology, Royal Jubilee Hospital, Victoria, British Columbia, Canada.
Eur J Cancer Clin Oncol. 1988 Dec;24(12):1885-9. doi: 10.1016/0277-5379(88)90102-2.
The central, intermediate and peripheral regions of 25 breast tumors were analyzed for estrogen receptors (ER) using a combined biochemical (BC)/immunohistochemical (IHC) micromethod. To optimize the regional comparison, the percentage carcinoma per sample (PCS) was evaluated and incorporated into the quantification of the ER. Correction of the measured ER for the PCS eliminated differences in receptor levels between the central and peripheral regions but not the intermediate region. Although the corrected BC-ER level in this region was found to be about 20% higher, the IHC method did not detect such a difference. Determination of the ER status at the actual growth front of a tumor, rather than in the intermediate region where ER levels appear to be highest, may be of greater clinical relevance. Intra-regional ER heterogeneity appears, however, to be particularly pronounced in this area of a tumor.
采用生化（BC）/免疫组织化学（IHC）联合微量方法对25例乳腺肿瘤的中央、中间和外周区域进行雌激素受体（ER）分析。为优化区域比较，评估了每个样本的癌组织百分比（PCS）并将其纳入ER的定量分析中。对测量得到的ER进行PCS校正后，消除了中央和外周区域之间受体水平的差异，但中间区域的差异未被消除。尽管发现该区域校正后的BC-ER水平高出约20%，但IHC方法未检测到这种差异。在肿瘤的实际生长前沿而非ER水平似乎最高的中间区域确定ER状态，可能具有更大的临床意义。然而，区域内ER异质性在肿瘤的这一区域似乎尤为明显。
